haroldpurplecrayon.bsky.social
@haroldpurplecrayon.bsky.social
Not surprising again inflammation correlates with worse outcomes, but I wonder how things might change or stay the same if they used continuous variables instead of dichotomous, and it's not clear whether the high/low cutoff was identical across studies
So many studies on ICI response prediction. Meta analysis of cytokines highlights IL6 and IL10 https://buff.ly/3X9FKPV Found with researchbriefing.com
Predictive value of serum cytokines in patients with non-small-cell lung cancer receiving anti-PD-1 blockade therapy: a meta-analysis
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. Immunotherapy, particularly PD-1 inhibitors, has revolutionized the treatment landscape for NSCLC. However, the...
buff.ly
February 20, 2025 at 10:52 AM
Not surprising again inflammation correlates with worse outcomes, but I wonder how things might change or stay the same if they used continuous variables instead of dichotomous, and it's not clear whether the high/low cutoff was identical across studies
Definitely something to think about when considering adjuvant or perioperative/neoadjuvant therapy
Even low levels of ctDNA may signal higher recurrence risk in early-stage lung adenocarcinoma. A new study shows that sensitive tests like NeXT Personal can help personalize treatment & improve outcomes. Early detection is crucial. #LungCancer #ctDNA ascopost.com/news/january...
February 18, 2025 at 5:07 PM
Definitely something to think about when considering adjuvant or perioperative/neoadjuvant therapy
Something for me to look into
Regulatory T cells converted from Th1 cells in tumors suppress #cancer immunity via CD39, say Sang-Nee Tan, Chen Dong and colleagues (Westlake University): https://buff.ly/3ED6d1G
#TumorImmunology #SolidTumors #LymphocyteBiology
#TumorImmunology #SolidTumors #LymphocyteBiology
February 12, 2025 at 6:29 PM
Something for me to look into
Something to read later
Review @natrevimmunol.bsky.social @laurenrodda.bsky.social @georgecelis.bsky.social
B cells in non-lymphoid tissues
www.nature.com/articles/s41...
B cells in non-lymphoid tissues
www.nature.com/articles/s41...
B cells in non-lymphoid tissues - Nature Reviews Immunology
B cells are major drivers of systemic immunity, but they also act locally in non-lymphoid organs. This Review highlights new insights into mechanisms of tissue B cell function as well as efforts to le...
www.nature.com
February 6, 2025 at 9:50 AM
Something to read later
Something for me to read later.
A new #ScienceImmunology Review discusses the mechanisms through which dendritic cells influence cytotoxic CD8+ T cell responses against cancer. scim.ag/3PU7hRo
Architects of immunity: How dendritic cells shape CD8+ T cell fate in cancer
DC–T cell interactions during priming influence CD8+ T cell fate, and DCs subsequently sustain T cell responses against cancer.
scim.ag
January 30, 2025 at 8:42 PM
Something for me to read later.
I wonder what would happen if all these federal workers called up OPM to ask for clarification on these and many other questions being asked? Would anyone answer the phone?
Unions and attorneys who represent federal employees are telling workers not to take the offer from the Trump administration to resign from their jobs by Feb. 6 and still be paid through September.
'Not a buyout': Attorneys and unions urge federal workers not to resign
Unions and attorneys who represent federal employees are telling workers not to take the offer from the Trump administration to resign from their jobs by Feb. 6 and still be paid through September.
www.npr.org
January 30, 2025 at 12:59 PM
I wonder what would happen if all these federal workers called up OPM to ask for clarification on these and many other questions being asked? Would anyone answer the phone?
Reposted by haroldpurplecrayon.bsky.social
Unions and attorneys who represent federal employees are telling workers not to take the offer from the Trump administration to resign from their jobs by Feb. 6 and still be paid through September.
'Not a buyout': Attorneys and unions urge federal workers not to resign
Unions and attorneys who represent federal employees are telling workers not to take the offer from the Trump administration to resign from their jobs by Feb. 6 and still be paid through September.
www.npr.org
January 29, 2025 at 7:29 PM
Unions and attorneys who represent federal employees are telling workers not to take the offer from the Trump administration to resign from their jobs by Feb. 6 and still be paid through September.
Amazing technique for molecular level 3D imaging. Can't wait to see how other mAbs work with this system, although it's still limited in speed(several hours for whole cell imaging)
Decoding the molecular interplay of CD20 and therapeutic antibodies with fast volumetric nanoscopy
https://buff.ly/3Wk6s7Q
The study’s insights enhance understanding of the molecular mechanisms behind mAb-induced cytotoxicity in B cell malignancies.
https://buff.ly/3Wk6s7Q
The study’s insights enhance understanding of the molecular mechanisms behind mAb-induced cytotoxicity in B cell malignancies.
buff.ly
January 15, 2025 at 11:23 AM
Amazing technique for molecular level 3D imaging. Can't wait to see how other mAbs work with this system, although it's still limited in speed(several hours for whole cell imaging)
Wow,I honestly would not have guessed that this would be possible. Amazing that the sarcoma could wall itself off and proliferate.
always double glove
Bizarre tumor immunology accident. Surgeon injures hand while resecting malignant histiocytoma and finds an inflamed mass at the site of prior injury. Tumor cells transplanted, patient & surgeon HLA mismatched causing intense yet insufficient host-vs-graft response: www.nejm.org/doi/full/10....
January 6, 2025 at 11:11 AM
Wow,I honestly would not have guessed that this would be possible. Amazing that the sarcoma could wall itself off and proliferate.
This is great and should apply to many diagnostic tests not just pathology
Tremendously important work
Patient-centered pathology reports improved patients' understanding of prostate biopsy results and their ability to accurately assess their cancer diagnosis and risk level, compared to standard pathology reports.
ja.ma/4a3c38z
ja.ma/4a3c38z
January 4, 2025 at 12:45 AM
This is great and should apply to many diagnostic tests not just pathology
Honestly was hoping for better results but then I'm looking a gift horse in it's mouth
CHRYSALIS-2 Cohort A: amivantamab + lazertinib in #EGFR NSCLC after osimertinib and chemotherapy @jtoonline.bsky.social (n=162). BICR RR 35%, CBR 58%, DOR 8.3m, PFS 4.5m, OS 14.8m, and CNS efficacy noted. AEs included rash in 81% (G3 10%), paronychia in 52%.
www.jto.org/article/S155...
www.jto.org/article/S155...
www.jto.org
January 2, 2025 at 12:20 PM
Honestly was hoping for better results but then I'm looking a gift horse in it's mouth
Reposted by haroldpurplecrayon.bsky.social
The burden of disease in the USA has evolved over the past three decades.
A recent study examines the burden of diseases, injuries, and risk factors in the USA and highlights the disparities in health outcomes across different states: tinyurl.com/5nsdjbht @ihmeuw.bsky.social
A recent study examines the burden of diseases, injuries, and risk factors in the USA and highlights the disparities in health outcomes across different states: tinyurl.com/5nsdjbht @ihmeuw.bsky.social
January 2, 2025 at 12:02 PM
The burden of disease in the USA has evolved over the past three decades.
A recent study examines the burden of diseases, injuries, and risk factors in the USA and highlights the disparities in health outcomes across different states: tinyurl.com/5nsdjbht @ihmeuw.bsky.social
A recent study examines the burden of diseases, injuries, and risk factors in the USA and highlights the disparities in health outcomes across different states: tinyurl.com/5nsdjbht @ihmeuw.bsky.social
Reposted by haroldpurplecrayon.bsky.social
🆕Just accepted at #JTO
www.jto.org/article/S155...
@jtoonline.bsky.social @iaslc.bsky.social @elsevierconnect.bsky.social #LCSM
www.jto.org/article/S155...
@jtoonline.bsky.social @iaslc.bsky.social @elsevierconnect.bsky.social #LCSM
In situ detection of PD1–PD-L1 interactions as a functional predictor for response to immune checkpoint inhibition in #NSCLC.
Emphasizes potential for more precise ICI treatment by shifting from static biomarker assessment to active immune pathway analysis. #LungCancer
https://buff.ly/41Xvbma
Emphasizes potential for more precise ICI treatment by shifting from static biomarker assessment to active immune pathway analysis. #LungCancer
https://buff.ly/41Xvbma
December 31, 2024 at 5:59 AM
Reposted by haroldpurplecrayon.bsky.social
Can patterns of progression on IO, inform future decisions?
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy
This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.
jamanetwork.com
December 26, 2024 at 8:55 PM
Can patterns of progression on IO, inform future decisions?
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
-1377pts from 5 ph 3 trials used to create 3 PD risk levels
- low (⬆️existing lesions), intermediate (new lesions), high (both)
- risk score assoc w post-PD OS across tumors
Prognostic, so far #LCSM
jamanetwork.com/journals/jam...
Reposted by haroldpurplecrayon.bsky.social
Time Toxicity of Systemic Anticancer Therapy for Metastatic Lung #Cancer in Routine Clinical Practice: A Nationwide Cohort Study.
ascopubs.org/doi/abs/10.1...
@ascocancer.bsky.social @ascopost.bsky.social
#CancerResearch #TimeToxicity #FinancialToxicity #CancerCare #LungCancer
ascopubs.org/doi/abs/10.1...
@ascocancer.bsky.social @ascopost.bsky.social
#CancerResearch #TimeToxicity #FinancialToxicity #CancerCare #LungCancer
December 22, 2024 at 9:42 PM
Time Toxicity of Systemic Anticancer Therapy for Metastatic Lung #Cancer in Routine Clinical Practice: A Nationwide Cohort Study.
ascopubs.org/doi/abs/10.1...
@ascocancer.bsky.social @ascopost.bsky.social
#CancerResearch #TimeToxicity #FinancialToxicity #CancerCare #LungCancer
ascopubs.org/doi/abs/10.1...
@ascocancer.bsky.social @ascopost.bsky.social
#CancerResearch #TimeToxicity #FinancialToxicity #CancerCare #LungCancer
Absolutely agree. We need more breakthroughs which come from unexpected directions rather than continue only with what we know. Can you imagine if the study of imaginary numbers centuries ago now used to make computer chips etc had to justify their research and explain how it will be used?
Night science is all about being OPEN to new ideas, while Day science is all about being CLOSED in a particular experimental design. It’s crazy hard, but the full scientific process requires us to be good at both.
December 15, 2024 at 11:19 AM
Absolutely agree. We need more breakthroughs which come from unexpected directions rather than continue only with what we know. Can you imagine if the study of imaginary numbers centuries ago now used to make computer chips etc had to justify their research and explain how it will be used?
Reposted by haroldpurplecrayon.bsky.social
1/4 @swog.org lung cancer trial, PRAGMATICA, closes early! This randomized trial enrolled 800 volunteers w stage 3-4 lung cancer in 21 months (goal was 700 in 24m). Tested chemo vs ramicirumab/pembrolizumab. Not applicable to every trial, but...
December 14, 2024 at 11:28 AM
1/4 @swog.org lung cancer trial, PRAGMATICA, closes early! This randomized trial enrolled 800 volunteers w stage 3-4 lung cancer in 21 months (goal was 700 in 24m). Tested chemo vs ramicirumab/pembrolizumab. Not applicable to every trial, but...
Reposted by haroldpurplecrayon.bsky.social
Can neoadjuvant chemo-immunotherapy convert unresectable NSCLC to resectable? Retrospective report of 113 pts with unresectable stage III NSCLC given chemo-IO. 70% went to surgery with 2y PFS rate 72%; 32% had pCR, 2y PFS rate for pCR 96%. #LCSM #OncSky
www.clinical-lung-cancer.com/article/S152...
www.clinical-lung-cancer.com/article/S152...
Conversion surgery for initially unresectable stage Ⅲ non-small cell lung cancer after induction treatment of immunochemotherapy: A multicenter study
Immuno-chemotherapy has demonstrated significant anti-tumor effects in patients with
resectable non-small cell lung cancer (NSCLC). Additionally, for patients initially
diagnosed with unresectable sta...
www.clinical-lung-cancer.com
December 4, 2024 at 10:02 AM
Can neoadjuvant chemo-immunotherapy convert unresectable NSCLC to resectable? Retrospective report of 113 pts with unresectable stage III NSCLC given chemo-IO. 70% went to surgery with 2y PFS rate 72%; 32% had pCR, 2y PFS rate for pCR 96%. #LCSM #OncSky
www.clinical-lung-cancer.com/article/S152...
www.clinical-lung-cancer.com/article/S152...
I really like this idea but honestly probably wouldn't find the time to recreate the new visualizations from published data but hopefully this can start a trend for improving visualizations for live presentations over print which are 2 very different formats
Tables and Tornadoes: The Best Tools for the Job?
Tables (sometimes BIG) are among most routinely used tools to show data like baseline characteristics & AEs, while “tornado plots” are a standard figure to display AEs & sometimes other variables.
But could we do better, esp for live talks? (1/8)
Tables (sometimes BIG) are among most routinely used tools to show data like baseline characteristics & AEs, while “tornado plots” are a standard figure to display AEs & sometimes other variables.
But could we do better, esp for live talks? (1/8)
December 5, 2024 at 6:20 AM
I really like this idea but honestly probably wouldn't find the time to recreate the new visualizations from published data but hopefully this can start a trend for improving visualizations for live presentations over print which are 2 very different formats
Reposted by haroldpurplecrayon.bsky.social
Intriguing data - are we giving more immunotherapy than we need to in peri-op regimens? https://buff.ly/41aMWhA . Found with researchbriefing.com.
Adjuvant Immunotherapy Does Not Improve Survival in Non-small Cell Lung Cancer with Major/Complete Pathological Response after Induction Immunotherapy
In patients with resectable non-small cell lung cancer (NSCLC), immune checkpoint inhibitor (ICI)-based regimens in both neoadjuvant and perioperative settings demonstrate survival benefit. To date,…
buff.ly
December 4, 2024 at 9:00 AM
Intriguing data - are we giving more immunotherapy than we need to in peri-op regimens? https://buff.ly/41aMWhA . Found with researchbriefing.com.
Reposted by haroldpurplecrayon.bsky.social
📢 Breaking news in #SCLC treatment!
Durvalumab is now FDA-approved for limited-stage SCLC based on the ADRIATIC trial. Adding 2 years of durvalumab after chemoradiation improves both PFS and OS (HR 0.73).
This approval marks an important step forward for patients with limited-stage SCLC! 💪
Durvalumab is now FDA-approved for limited-stage SCLC based on the ADRIATIC trial. Adding 2 years of durvalumab after chemoradiation improves both PFS and OS (HR 0.73).
This approval marks an important step forward for patients with limited-stage SCLC! 💪
December 5, 2024 at 12:08 AM
📢 Breaking news in #SCLC treatment!
Durvalumab is now FDA-approved for limited-stage SCLC based on the ADRIATIC trial. Adding 2 years of durvalumab after chemoradiation improves both PFS and OS (HR 0.73).
This approval marks an important step forward for patients with limited-stage SCLC! 💪
Durvalumab is now FDA-approved for limited-stage SCLC based on the ADRIATIC trial. Adding 2 years of durvalumab after chemoradiation improves both PFS and OS (HR 0.73).
This approval marks an important step forward for patients with limited-stage SCLC! 💪
Reposted by haroldpurplecrayon.bsky.social
Could have implications for other oral therapies including anti cancer medications although there could certainly be differences in how patients approach adherence to cardiovascular vs oncologic problems
Text message reminders targeting patients who delay refilling their cardiovascular medications did not improve medication adherence based on pharmacy refill data or reduce clinical events at 12 months.
ja.ma/4irtinM
ja.ma/4irtinM
December 2, 2024 at 6:09 PM
Could have implications for other oral therapies including anti cancer medications although there could certainly be differences in how patients approach adherence to cardiovascular vs oncologic problems
Reposted by haroldpurplecrayon.bsky.social
Text message reminders targeting patients who delay refilling their cardiovascular medications did not improve medication adherence based on pharmacy refill data or reduce clinical events at 12 months.
ja.ma/4irtinM
ja.ma/4irtinM
December 2, 2024 at 4:57 PM
Text message reminders targeting patients who delay refilling their cardiovascular medications did not improve medication adherence based on pharmacy refill data or reduce clinical events at 12 months.
ja.ma/4irtinM
ja.ma/4irtinM
I think this reflects the grading system overall in the United States (why is the typical average 75 instead of 50 in range from 0-100?). I recall the Garison Keilor quote about Lake Woebegone where "all kids are above average...".
I see a lot of funny quotes about the top of the list, but look at the bottom. THIS IS WHAT IS WRONG WITH AMERICA. Somehow “bottom 50%” (like all incoming political appointees) is “Satisfactory”?!?!?
No. No, it ain’t.
No. No, it ain’t.
PhD programs, please stop with this nonsense...
December 1, 2024 at 11:26 PM
I think this reflects the grading system overall in the United States (why is the typical average 75 instead of 50 in range from 0-100?). I recall the Garison Keilor quote about Lake Woebegone where "all kids are above average...".